



## **Jonathan Peacock**

**Independent Director since 2021**

**Chair of the Board since 2023**

**Chair of the Audit Committee since 2021  
(ad-interim since 2023)**

**Date of birth:** 1958

**Nationality:** British & American

**Gender:** Male

**End of term:** 2025

### **Introduction & Professional experience**

Mr. Jonathan Peacock is Chairman of the Board of Directors of Avantor Inc\*, where he has served as Chair of the Audit and Finance Committee, and a member of the Nominating and Governance Committee. He also serves on the Board of 2 private companies, Bluesphere Bio, as Chairman, and Real Chemistry.

Mr. Jonathan Peacock served as director of Genmab A/S\*, where he was a member of the Audit and Finance Committee and the Compensation Committee till November 2021.

From 2014 to May 2021, Mr. Peacock served as the Chairman of Bellerophon Therapeutics, Inc.\*, a clinical stage biotherapeutics company, and was the CEO from 2014 to 2016. He also served as Chairman of Arix Bioscience plc\* from 2016-2020 and as Chair of the Audit and Finance Committee of Kite Pharma\* from 2014-17.

Mr. Peacock held Global CFO roles at Amgen\* and Novartis Pharma and leadership roles in Strategy and Corporate Finance as a partner at McKinsey and Price Waterhouse. He has experience in emerging Biotechnology, big Pharma and Corporate Finance in Europe, the US and Asia. He also has extensive IPO and fund-raising experience on NASDAQ, NYSE and LSE.

### **Education**

Mr. Peacock earned a M.A. in Economics from the University of St. Andrews in Scotland and is a Chartered Accountant.



**Main external appointments**

Chairman of the Board of Directors of Avantor, Inc\*

Chairman of the Board of Directors of Bluesphere Bio, Inc.

Board member of Real Chemistry

\* *Listed company*

